Publications by authors named "Erika Todter"
Study Objective: The real-world effectiveness and safety of a 0/1-hour accelerated protocol using high-sensitivity cardiac troponin (hs-cTn) to exclude myocardial infarction (MI) compared to routine care in the United States is uncertain. The objective was to compare a 0/1-hour accelerated protocol for evaluation of MI to a 0/3-hour standard care protocol.
Methods: The RACE-IT trial was a stepped-wedge, randomized trial across 9 emergency departments (EDs) that enrolled 32,609 patients evaluated for possible MI from July 2020 through April 2021.
Article Synopsis
- The LAMP trial investigated whether adding pulsed-xenon UV (PX-UV) disinfection to standard cleaning reduces healthcare-associated infections (HAIs), focusing on environmentally implicated HAIs (eiHAIs).
- Conducted in two hospitals, the study included over 25,000 patients and compared the incidence of eiHAIs between the PX-UV group and a control group, finding no significant differences in infection rates.
- Ultimately, the trial concluded that adding PX-UV to terminal cleaning did not effectively reduce eiHAIs, suggesting the need for further research on hospital disinfection methods.
Background: Hepatocellular Carcinoma (HCC) is a malignancy with increasing incidence and morbidity. For patients with a poor prognosis, engagement with advanced care planning and end-of life (EOL) services (I.e.
View Article and Find Full Text PDFIdentification of specific risk factors for severe coronavirus disease 2019 (COVID-19) is crucial for prevention of poor outcomes and mortality. This retrospective cohort study of patients hospitalized with COVID-19 demonstrated that older age, male sex, Black race, diabetes, elevated BMI, and elevated inflammatory markers were correlated with critical illness in COVID-19. Older age, male sex, diabetes, and inflammatory markers, but not elevated BMI, were associated with mortality.
View Article and Find Full Text PDFBackground: Finite clinical data and understanding of COVID-19 immunopathology has led to limited, opinion-based recommendations for the management of patients with immune-mediated inflammatory disease (IMID) receiving immunosuppressive (IS) therapeutics.
Objective: To determine if IS therapeutic type affects COVID-19 risk among patients with IMID.
Methods: We conducted a retrospective cohort analysis of Henry Ford Health System patients tested for COVID-19 between February 1 and April 18, 2020, treated with IS medication for IMID.